Vaginal Bioadhesive Danazol Composition for Peritoneal Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for endometriosis and other endometrial disorders are limited in efficacy and often associated with high recurrence and systemic side effects, necessitating a need for therapeutics that can effectively target peritoneal lesions while minimizing systemic exposure.
Innovation Solution
Compositions comprising micronized danazol, polyglycolyzed oleic glyceride, cellulose polymer, and water-insoluble bioadhesives are vaginally administered to localize the active agent to the peritoneal tissue, achieving high concentrations in pelvic fluid and reducing systemic levels, thereby treating endometrial diseases and reducing pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If oral administration of current therapeutics is used, then treatment coverage is provided, but systemic side effects increase and recurrence rate remains high
Solution Approach 1:
The patent applies local quality by formulating the drug composition specifically for vaginal administration to target peritoneal lesions locally. The composition includes micronized danazol with specific particle size distribution (D10: 1-10 μm, D50: 10-50 μm, D90: 50-100 μm) and is delivered via vaginal route to achieve high local concentrations in peritoneal fluid and tissue while minimizing systemic absorption, thereby reducing systemic side effects while maintaining treatment efficacy
Solution Approach 2:
The patent uses an intermediary delivery system consisting of vaginal cream base and bioadhesive components. The cream formulation includes water-soluble and water-insoluble bioadhesives that facilitate localized drug retention and release. This intermediary system enables controlled delivery of danazol to peritoneal tissue through the vaginal route, acting as a mediator between the drug and target tissue to achieve therapeutic concentrations locally while limiting systemic exposure
2Quantity of substance
If high concentration of active agent is delivered to peritoneal tissue, then treatment efficacy improves, but systemic circulation levels increase causing adverse effects
Solution Approach 1:
The patent applies segmentation by dividing the drug delivery system into multiple functional components: micronized active agent particles (segmented by size distribution), water-soluble bioadhesive components, and water-insoluble bioadhesive components. This segmentation allows different components to perform specific functions - the micronized particles provide high local concentration while the bioadhesives control release and retention, collectively achieving high peritoneal concentration with limited systemic exposure
Solution Approach 2:
The patent utilizes parameter changes by controlling the particle size distribution of danazol (D10: 1-10 μm, D50: 10-50 μm, D90: 50-100 μm) and adjusting the ratios of water-soluble to water-insoluble bioadhesives in the cream formulation. These parameter optimizations enable the system to achieve high local drug concentrations through enhanced permeation and retention while maintaining controlled release kinetics that prevent excessive systemic absorption and adverse effects
3Quantity of substance
If vaginal administration of polybioadhesive gel is used, then active agent localization to peritoneal tissue is achieved, but formulation complexity increases
Solution Approach 1:
The patent merges multiple functional components into a single integrated vaginal cream formulation. The combination includes micronized danazol particles, water-soluble bioadhesives, water-insoluble bioadhesives, and cream base ingredients (carboxymethylcellulose, carbomer, poloxamer) all formulated together in one applicatable composition. This merging approach achieves effective active agent localization to peritoneal tissue while presenting a unified, user-friendly formulation that simplifies administration compared to multiple separate agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaginal administration method achieves high peritoneal fluid and tissue concentrations with low systemic circulation, maintaining ovarian function and reducing pain associated with endometriosis, while minimizing systemic adverse effects.
Implementation Method 1
one or more water-insoluble bioadhesives, wherein at least one water-insoluble bioadhesive is polycarbophil
Implementation Method 2
a polybioadhesive gel comprising: (a) an active agent or a salt thereof; (b) one or more water-insoluble bioadhesive; (c) at least one oleogel; and (d) at least one aqueous gel
Data Source
AI summary
Disclosed herein are compositions for administering vaginally of an active agent or a salt to a subject comprising the active agent or salt thereof, a bioadhesive, and an emulsion. Provided herein are methods treating a disease of condition by administering vaginally to a subject a pharmaceutical composition, and kits comprising the pharmaceutical composition. Further provided are methods of localizing an active agent to the peritoneal cavity of a subject while minimizing systemic circulation of the active agent.